



US009511116B2

(12) **United States Patent**
Hellerbrand et al.

(10) **Patent No.:** US 9,511,116 B2
(45) **Date of Patent:** Dec. 6, 2016

(54) **STABLE MIA/CD-RAP FORMULATION**(71) Applicant: **Scil Technology GmbH**, Martinsried (DE)(72) Inventors: **Klaus Hellerbrand**, Moorenweis (DE); **Rainer Sigl**, Puchheim (DE)(73) Assignee: **SCIL Technology GMBH**, Martinsried (DE)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **13/661,743**(22) Filed: **Oct. 26, 2012**(65) **Prior Publication Data**

US 2013/0137639 A1 May 30, 2013

Related U.S. Application Data

(63) Continuation of application No. PCT/EP2011/056622, filed on Apr. 27, 2011.

(30) **Foreign Application Priority Data**

Apr. 27, 2010 (EP) 10161160

(51) **Int. Cl.**

A61K 38/00	(2006.01)
A61K 38/16	(2006.01)
A61K 38/17	(2006.01)
A61K 9/00	(2006.01)
A61K 47/22	(2006.01)
C07K 14/47	(2006.01)
C07K 14/78	(2006.01)

(52) **U.S. Cl.**

CPC	A61K 38/1709 (2013.01); A61K 9/0019 (2013.01); A61K 47/22 (2013.01); C07K 14/4703 (2013.01); C07K 14/78 (2013.01); A61K 9/0024 (2013.01); A61K 38/00 (2013.01)
-----------	---

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,244,943 A *	1/1981	Yamahira et al. 424/94.3
4,374,763 A *	2/1983	Takagi 530/390.5

5,580,856 A	12/1996	Prestrelski et al.
5,770,366 A	6/1998	Bogdahn et al.
6,583,272 B1 *	6/2003	Bailon 530/397
2002/009493 A1 *	1/2002	Schwendeman et al. 424/486
2002/0103360 A1 *	8/2002	Pan et al. 536/23.5
2003/0091583 A1	5/2003	Hubert et al.
2003/0180287 A1	9/2003	Gombotz et al.
2003/0202972 A1	10/2003	Andya et al.
2005/0020498 A1 *	1/2005	Flores et al. 514/12
2009/0060906 A1 *	3/2009	Barry et al. 424/131.1

FOREIGN PATENT DOCUMENTS

EP	0 315 968	5/1989
WO	WO 01/55332	8/2001
WO	2004/015078	2/2004
WO	2007/109221	9/2007
WO	2008/040556	4/2008
WO	WO 2008/040557 A1 *	4/2008

OTHER PUBLICATIONS

Shiraki et al. (2004, Eur. J. Biochem. 271:3242-3247).*

Arakawa et al. (2003, Biochem. Biophys. Res. Commun. 304: 148-152).*

Schmid et al. (2010, Cell Death and Disease 1: 1-10).*

PCT Search Report for International Application No. PCT/EP2011/056622; mailed on Apr. 11, 2012.

Arakawa T., et al., (2007) *Suppression of protein interactions by arginine: A proposed mechanism of the arginine effects*, Biophysical Chemistry 127: 1-8.Schubert T., et al., (2010) *Modulation of cartilage differentiation by melanoma inhibitory activity/cartilage-derived retinoic acid-sensitive protein (MIA/CD-RAP)*, Experimental and Molecular Medicine 42: 166-174.

Lougheed, J.C., et al. (2002) "Solution structure and dynamics of melanoma inhibitory activity protein", Journal of Biomolecular NMR 22: pp. 211-223.

* cited by examiner

Primary Examiner — Elizabeth C Kemmerer

(74) Attorney, Agent, or Firm — Kagan Binder, PLLC

(57) **ABSTRACT**

The present invention relates to stable aqueous formulations comprising at least 5 mg/mL CD-RAP and a charged amino acid, said amino acid preferably having a net charge at a pH between about 6 and 8. The ingredients of the formulation preferably provide stability over repeated freeze-thaw cycles. In a preferred aspect, the formulation is for use in therapy, preferably for use in the treatment of inflammatory disorders, preferably osteoarthritis. Furthermore, a kit comprising the formulation of the invention is provided.

18 Claims, 11 Drawing Sheets